Loading...
XTSXGSD
Market cap16mUSD
Jan 09, Last price  
0.17CAD
1D
3.13%
1Q
3.13%
IPO
-72.50%
Name

Devonian Health Group Inc

Chart & Performance

D1W1MN
XTSX:GSD chart
P/E
—
P/S
1.34
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.58%
Rev. gr., 5y
24.58%
Revenues
18m
+659.60%
0003,199,9595,937,7542,143,1551,474,6902,305,1882,345,38917,815,509
Net income
-1m
L-73.38%
-89,010-1,823,046-4,375,715-3,187,068-2,979,416-4,374,776-3,346,380-3,448,302-4,599,607-1,224,636
CFO
6m
P
-32,680-2,141,117-2,430,669-2,143,231-1,157,915-2,027,627-1,833,266-2,871,582-4,356,2465,633,834
Earnings
Mar 25, 2025

Profile

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
URL
https://groupedevonian.com/
IPO date
Sep 09, 2014
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑06
Income
Revenues
17,816
659.60%
2,345
1.74%
2,305
56.32%
Cost of revenue
18,674
6,745
5,335
Unusual Expense (Income)
NOPBT
(858)
(4,399)
(3,030)
NOPBT Margin
Operating Taxes
937
Tax Rate
NOPAT
(858)
(4,399)
(3,967)
Net income
(1,225)
-73.38%
(4,600)
33.39%
(3,448)
3.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
708
1,163
10,763
BB yield
-20.09%
Debt
Debt current
2,120
3,602
6
Long-term debt
296
167
4,294
Deferred revenue
Other long-term liabilities
Net debt
(7,446)
(1,294)
(3,505)
Cash flow
Cash from operating activities
5,634
(4,356)
(2,872)
CAPEX
(4)
(79)
Cash from investing activities
(4)
5,000
(5,079)
Cash from financing activities
(830)
1,614
10,411
FCF
(644)
(4,225)
(4,930)
Balance
Cash
9,863
5,063
7,805
Long term investments
Excess cash
8,972
4,946
7,690
Stockholders' equity
3,187
10,483
12,596
Invested Capital
13,521
12,976
12,861
ROIC
ROCE
EV
Common stock shares outstanding
135,566
119,028
Price
0.19
 
0.45
-6.25%
Market cap
53,563
25.60%
EV
50,058
EBITDA
(186)
(3,976)
(2,166)
EV/EBITDA
Interest
380
460
937
Interest/NOPBT